NASDAQ:IVA

Inventiva (IVA) Stock Price, News & Analysis

Inventiva logo
$3.14 -0.31 (-9.10%)
Closing price 03:58 PM Eastern
Extended Trading
$3.14 +0.01 (+0.29%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Inventiva Stock (NASDAQ:IVA)

Advanced

Key Stats

Today's Range
$3.13
▼
$3.44
50-Day Range
$2.87
▼
$4.03
52-Week Range
$2.82
▼
$7.29
Volume
3.02 million shs
Average Volume
1.15 million shs
Market Capitalization
$749.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.67
Consensus Rating
Moderate Buy

Company Overview

Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial. The company expects topline trial results in Q4 2026 and, if results are positive, plans to pursue U.S. regulatory approval, with a potential commercial launch in 2028.

Inventiva was founded by former Abbott Laboratories executives and became a French public limited company in 2016. Its American Depositary Shares trade on the Nasdaq Global Market under the symbol IVA, while its ordinary shares are listed on Euronext Paris. The company is led by Chief Executive Officer Andrew Obenshain, who succeeded co-founder Frédéric Cren in October 2025.

AI Generated. May Contain Errors.

Inventiva Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

IVA MarketRank™: 
2.666758166345 of 5 stars

Inventiva scored higher than 53% of companies evaluated by MarketBeat, and ranked 395th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Inventiva has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Inventiva has a consensus price target of $14.67, representing about 367.7% upside from its current price of $3.14.

  • Amount of Analyst Coverage

    Inventiva has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Inventiva's stock forecast and price target.
  • Earnings Growth

    Earnings for Inventiva are expected to decrease in the coming year, from ($0.75) to ($0.85) per share.

  • Percentage of Shares Shorted

    6.36% of the float of Inventiva has been sold short.
  • Short Interest Ratio / Days to Cover

    Inventiva has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Inventiva has recently increased by 26.92%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Inventiva does not currently pay a dividend.

  • Dividend Growth

    Inventiva does not have a long track record of dividend growth.

  • News Sentiment

    Inventiva has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Inventiva this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for IVA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 8 people have added Inventiva to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Inventiva insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    19.06% of the stock of Inventiva is held by institutions.

  • Read more about Inventiva's insider trading history.
Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IVA Stock News Headlines

HC Wainwright Comments on Inventiva FY2026 Earnings
Your father's savings lost half their value after 1971.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
See More Headlines

IVA Stock Analysis - Frequently Asked Questions

Inventiva's stock was trading at $4.65 at the beginning of 2026. Since then, IVA stock has decreased by 32.6% and is now trading at $3.1360.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) issued its quarterly earnings data on Friday, August, 14th. The company reported ($0.15) EPS for the quarter. The business had revenue of $745.26 thousand for the quarter.

Inventiva (IVA) raised $108 million in an IPO on Friday, July 10th 2020. The company issued 7,478,261 shares at a price of $13.40-$15.40 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

Top institutional shareholders of Inventiva include Aberdeen Group plc (1.32%), Nantahala Capital Management LLC (1.26%), Marshall Wace LLP (0.95%) and Integral Health Asset Management LLC (0.54%).

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inventiva investors own include Larimar Therapeutics (LRMR), NVIDIA (NVDA), Ondas (ONDS), Advanced Micro Devices (AMD), Iovance Biotherapeutics (IOVA), Taysha Gene Therapies (TSHA) and Black Diamond Therapeutics (BDTX).

Company Calendar

Last Earnings
9/28/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IVA
CIK
1756594
Fax
N/A
Employees
77
Year Founded
2011

Price Target and Rating

High Price Target
$18.00
Low Price Target
$12.00
Potential Upside/Downside
+367.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.90
Current Ratio
3.81
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$5.07 million
Price / Sales
147.92
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.22) per share
Price / Book
-14.25

Miscellaneous

Outstanding Shares
239,150,000
Free Float
162,621,000
Market Cap
$749.97 million
Optionable
Optionable
Beta
0.76

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:IVA) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners